Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ABSK061 and ABSK043 in Advanced Solid Tumors with FGFR2/3 Alterations
NCT06632262Phase 2Recruiting
- Sponsor
- Abbisko Therapeutics
- Start
- Nov 2024
- Primary completion
- Nov 2029
- Modality
- Immune Checkpoint Inhibitors, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of lavengratinib and lumipodlin in gastric cancer (GC), gastroesophageal junction cancer, urothelial carcinoma (UC) and 2 more (4 cohorts), sponsored by Abbisko Therapeutics. Primary endpoints: Incidence of Dose Limiting Toxicity, Tolerability of ABSK061 + ABSK043 + CAPOX and 2 more. Started Nov 2024; status: recruiting.
02
Drugs
lavengratiniblumipodlin
03
Conditions
gastric cancer (GC)gastroesophageal junction cancerurothelial carcinoma (UC)non-small cell lung cancer (NSCLC)solid tumor
Beyond the preview
Go deeper on NCT06632262.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06632262.